Hematology Transfusion and Cell Therapy · Oct 2026

Frailty as a marker of impaired quality of life in multiple myeloma

By Bretas G, BAPTISTA RLR, LIMA ACDAA et al.

INTRODUCTION: Multiple myeloma (MM) is associated with high morbidity and a substantial impact on patients' quality of life (QV). The disease is more prevalent in the older population, which has more comorbidities and greater frailty, factors that may affect the severity of adverse events (EAs) and the perception of QV. OBJECTIVES: This observational study aims to assess frailty status in patients with MM and its cross-sectional association with QV. MATERIALS AND METHODS: This was an observational study with cross-sectional analyses, including patients older than 18 years with a diagnosis of MM between March 2023 and May 2026 at Pedro Ernesto University Hospital (HUPE). Clinical and sociodemographic data were collected from medical records, and the International Myeloma Working Group (IMWG) Frailty Score was calculated for each patient. The generic QV questionnaire, EORTC QLQ-C30, and the MM-specific module, QLQ-MY20, were administered at diagnosis or at the earliest feasible time. The treatment EAs domain of the QLQ-MY20 was administered after treatment initiation. Data were analyzed using SPSS version 21, with descriptive analyses, and associations between frailty and QV were assessed. RESULTS: To date, data have been collected from 121 patients, of whom 64 (52.9%) were classified as frail according to the IMWG Frailty Score. There was a similar distribution between the sexes. Frail patients were older at diagnosis than nonfrail patients (69.9 ± 11.0 vs. 63.6 ± 9.2 years; p=0.001). Fractures and spinal cord compression were more frequent among frail patients (OR 2.13; 95% CI 1.03–4.41; p=0.042 and OR 4.11; 95% CI 1.67–10.09; p=0.001, respectively). No significant differences between the groups were observed in creatinine (2.32 ± 1.96 vs. 2.23 ± 2.26 mg/dL; p=0.820) or calcium (10.7 ± 2.1 vs. 10.2 ± 1.7 mg/dL; p=0.197) levels, and hemoglobin levels were slightly lower (9.1 ± 2.2 vs. 10.0 ± 2.5 g/dL; p=0.046). On the EORTC QLQ-C30 questionnaire, frail patients had lower functioning scores (47.4 ± 21.4 vs. 70.9 ± 16.3; p<0.001), lower global QV scores (45.7 ± 29.6 vs. 64.3 ± 26.4; p=0.001), and a higher symptom burden (41.6 ± 18.6 vs. 25.3 ± 14.3; p<0.001). On the QLQ-MY20 module, frail patients also had worse multiple myeloma-specific QV, with higher disease symptom scores (50.7 ± 29.9 vs. 29.0 ± 25.3; p<0.001), lower body image scores (51.4 ± 42.4 vs. 66.7 ± 35.6; p=0.036), and lower future perspective scores (33.7 ± 31.9 vs. 47.8 ± 29.0; p=0.014). There was no statistically significant difference in treatment adverse effects scores (29.0 ± 18.5 vs. 22.0 ± 18.4; p=0.078). In all domains with statistically significant differences, the magnitude of the differences also exceeded previously published thresholds for the minimal clinically important difference. DISCUSSION: Frailty was associated with worse global QV, lower functioning, more symptoms, and a worse future perspective, with clinical relevance. The absence of an association with creatinine, calcium, and EAs, together with only slightly lower hemoglobin, suggests that this impact is not solely due to biochemical severity or toxicity, nor does it justify indiscriminate treatment reduction. CONCLUSION: Systematic frailty assessment may identify patients with greater QV impairment and guide individualized care.

doi.org/10.1016/j.htct.2026.107872Open accessBiomarkers

AgingResearch.News